Atovin 10mg

Tablet
Atorvastatin Calcium
Alco Pharma

Other Strength:
- Atovin 20mg

Alternative:
- Tiginor 10mg
- Anzitor 10mg
- Xelpid 10mg
- Locol 10mg
- Atasin 10mg
- Lipistat 10mg
- Stacor 10mg
- TCL-R 10mg
- Zuvas 10mg
- Vastor 10mg
- Liptor 10mg



Atovin
Description:
Atovin is a preparation of Atorvastatin Calcium, which is a synthetic lipid lowering agent. Atorvastatin reduces levels of "bad" cholesterol (low-density lipoprotein, or LDL) and triglycerides in the blood, while increasing levels of "good" cholesterol (high-density lipoprotein, or HDL).

Composition:
Atovin 10 Tablet: Each tablet contains Atorvastatin Calcium USP eq. to Atorvastatin 10 mg.

Atovin 20 Tablet: Each tablet contains Atorvastatin Calcium USP eq. to Atorvastatin 20 mg.

Indication/Use:
Atovin is indicated as an adjunct to diet for reduction of elevated total cholesterol, LDL-cholesterol, apolipoprotein B, and triglycerides in patients with-

1.Primary hypercholesterolemia [heterozygous familial and non-familial hypercholesterolemia and mixed dyslipidemia (Fredrickson types IIa and IIb)]

2.Elevated serum TG levels (Fredrickson type IV)

3.Primary dysbetalipoproteinemia (Fredrickson type III) who do not respond adequately to diet.

4.Homozygous familial hypercholesterolemia as an adjunct to other lipid-lowering treatments (eg, LDL apheresis) or if such treatments are unavailable.

Dosage Guideline:
Adult:
Patients should be placed on a standard cholesterol-lowering diet before receiving Atovin and should continue on this diet during treatment with Atovin. The usual starting dose for all the indications is 10 mg once daily. The doses range is 10 to 80 mg once daily. Doses should be individualised according to baseline LDL-C levels, the goal of therapy, and patient response. Adjustment of dosage should be made at
intervals of 4 weeks or more. Doses may be given at any time of day with or without food.
Children:
Treatment experience in a paediatric population with dose of Atovin up to 80 mg/day is limited.
Geriatric (>70 years) use:
The safety and efficacy of Atovin in this population is as similar as < 70 years of age patients with the dose upto 80 mg/day.
In patients with Renal Insufficiency:
No dosage adjustment is required.

Side Effects:
Atorvastatin is generally well tolerated. Myalgia, constipation, flatulence, dyspepsia and abdominal pain are most common side effects. In clinical trials pancreatitis, liver toxicity and dizziness occur in some cases.

Contraindication:
Atorvastatin is contraindicated in patients with hypersensitivity to any component of this medication, active liver disease or unexplained persistent elevations of serum transaminases, during pregnancy, while breast-feeding, and in women of child-bearing potential not using appropriate contraceptive measures.

Drug Interaction:
The risk of myopathy during treatment with drugs in this class is increased with concurrent administration of cyclosporin, fibric acid derivatives, erythromycin, azole antifungals, or niacin (nicotinic acid). These risks may also occur when combining these drugs with Atorvastatin. No clinically significant interactions were seen when Atorvastatin was administered with antihypertensives and or hypoglycemic agents. Caution should also be exercised when Atorvastatin is administered with inhibitors of P450 3A4 (macrolide antibiotics and azole antifungals). The effect of inducers of cytochrome P450 3A4 (rifampicin or phenytoin) on Atorvastatin is unknown. Patients should be closely monitored if Atorvastatin is added to digoxin, erythromycin, oral contraceptives, colestipol, antacid and warfarin.
No interaction was found with cimetidine.

Use in Pregnancy & Lactation:
Atorvastatin is contraindicated in pregnancy and while breast-feeding. Women of child bearing potential should use appropriate contraceptive measures. If the woman becomes pregnant while taking Atorvastatin, it should be discontinued.

Over Dose:
In case of acute overdose no specific data is available. The patient should be treated symptomatically.

Precaution:
Atorvastatin may cause an elevation in serum creatinephosphokinase (CPK) levels. This should be considered in the differential diagnosis of chest pain in patients on therapy with Atorvastatin. Uncomplicated myalgia has been reported in Atorvastatin treated patients. Atorvastatin therapy should be discontinued if markedly elevated CPK levels occur or myopathy is diagnosed or suspected.

Therapeutic Class:
Lipid Lowering Agent

Dosage Form:
Tablet



এই পাতাটি ১৭৩ বার দেখা হয়েছে